Characteristic | OR | 95% CI | P value |
Osteoporosis | |||
Age, 31 December 2020 | 1.09 | 1.07 to 1.10 | <0.001 |
Gender, female (vs male) | 1.23 | 0.77 to 2.02 | 0.4 |
Socioeconomic status | |||
Low | — | — | |
Medium | 0.88 | 0.57 to 1.38 | 0.6 |
High | 0.87 | 0.55 to 1.39 | 0.6 |
Smoking status, ever (vs never) | 1.03 | 0.64 to 1.64 | 0.9 |
Disease duration, years | 1.08 | 1.06 to 1.11 | <0.001 |
HCQ cumulative annual dose, ≥300 tabs per year (vs<300) | 1.63 | 1.18 to 2.27 | 0.003 |
Prednisone cumulative daily dose | |||
0–≤5 mg/day | — | — | |
<5–≤7.5 mg/day | 3.13 | 1.92 to 5.13 | <0.001 |
>7.5 mg/day | 5.37 | 3.05 to 9.52 | <0.001 |
AUC 0.824; Hosmer-Lemshow GOF p value=0.8403 | |||
Cardiovascular disease | |||
Age, 31 December 2020 | 1.04 | 1.02 to 1.05 | <0.001 |
Gender, female (vs male) | 0.28 | 0.18 to 0.43 | <0.001 |
Socioeconomic status | |||
Low | — | — | |
Medium | 0.7 | 0.45 to 1.13 | 0.14 |
High | 0.6 | 0.36 to 0.99 | 0.044 |
Smoking status, ever (vs never) | 1.68 | 1.04 to 2.67 | 0.031 |
Hypertension | 1.9 | 1.29 to 2.81 | 0.001 |
Diabetes | 2.05 | 1.22 to 3.44 | 0.007 |
Disease duration, years | 1.04 | 1.01 to 1.08 | 0.005 |
HCQ cumulative annual dose, ≥300 tabs per year (vs<300) | 1.19 | 0.83 to 1.71 | 0.4 |
Prednisone cumulative daily dose | |||
0–≤5 mg/day | — | — | |
<5–≤7.5 mg/day | 1.74 | 1.03 to 2.88 | 0.035 |
>7.5 mg/day | 1.68 | 0.91, 3.01 | 0.088 |
AUC 0.778; Hosmer-Lemshow GOF p value=0.8319 | |||
Hypertension | |||
Age, 31 December 2020 | 1.09 | 1.08 to 1.11 | <0.001 |
Gender, female (vs male) | 0.61 | 0.39 to 0.97 | 0.035 |
Socioeconomic status | |||
Low | — | — | |
Medium | 0.44 | 0.29 to 0.67 | <0.001 |
High | 0.39 | 0.25 to 0.61 | <0.001 |
Smoking status, ever (vs never) | 0.93 | 0.58 to 1.46 | 0.8 |
Disease duration, years | 1.04 | 1.02 to 1.07 | 0.002 |
HCQ cumulative annual dose, ≥300 tabs per year (vs<300) | 1.26 | 0.91 to 1.74 | 0.2 |
Prednisone cumulative daily dose | |||
0–≤5 mg/day | — | — | |
<5–≤7.5 mg/day | 2.39 | 1.47 to 3.92 | <0.001 |
>7.5 mg/day | 1.71 | 0.95 to 3.03 | 0.068 |
AUC 0.820; Hosmer-Lemshow GOF p value=0.08956 | |||
Diabetes | |||
Age, 31 December 2020 | 1.06 | 1.04 to 1.08 | <0.001 |
Gender, female (vs male) | 0.57 | 0.32 to 1.06 | 0.065 |
Socioeconomic status | |||
Low | — | — | |
Medium | 0.53 | 0.29 to 0.99 | 0.041 |
High | 0.55 | 0.29 to 1.05 | 0.067 |
Smoking status, ever (vs never) | 2.21 | 1.20 to 3.92 | 0.009 |
Disease duration, years | 0.96 | 0.93 to 1.00 | 0.077 |
HCQ cumulative annual dose, ≥300 tabs per year (vs<300) | 0.86 | 0.53 to 1.42 | 0.6 |
Prednisone cumulative daily dose | |||
0–≤5 mg/day | — | — | |
<5–≤7.5 mg/day | 1.79 | 0.87 to 3.49 | 0.1 |
>7.5 mg/day | 3.09 | 1.41 to 6.33 | 0.003 |
AUC 0.776; Hosmer-Lemshow GOF p value=0.8259.
AUC, area under the curve; GC, glucocorticoid; GOF, goodness of fit; HCQ, hydroxychloroquine.